An exceptional opportunity exists for a drug development company to co-develop a drug candidate validation program in the field of anti-mitotic cancer therapeutics.
BPH Energy recently established a high-content drug screening and development platform at its Molecular Discovery Systems laboratory. In trial runs of this new technology, BPH Energy's Chief Scientist has identified a new class of anti-mitotic cancer drug. In light of the clinical success of anti-mitotic drugs, such as Taxol®, the giants of the pharmaceutical industry (e.g. Amgen, AstraZeneca, Boehringer, Glaxo, Johnson, Merck, Millenium, Pfizer, Roche, Sanofi, Schering) have invested heavily in new anti-mitotic therapeutics. Importantly, pharmaceutical and functional characterisation of BPH Energy's new anti-mitotic drug clearly indicates that it has the potential to match some of the best anti-mitotic cancer drugs discovered to date.
Furthermore, since BPH Energy's new drug was derived from a small sample of synthetic molecules, the recent discovery indicates that the technology and expertise are at hand at MDSystems to establish a drug discovery pipeline that has the capacity to deliver a multitude of new and highly valuable anti-cancer drug candidates.
